FR0010609263 - Common Stock
MAUNA KEA TECHNOLOGIES
EPA:MKEA (8/7/2023, 7:00:00 PM)
0.62
0 (0%)
Mauna Kea Technologies SA engages in the design, development, and sale of optical biopsy devices and tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts primarily in cancer patients. The company is headquartered in Paris, Ile-De-France and currently employs 56 full-time employees. The company went IPO on 2011-07-05. The firm focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The firm markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.
MAUNA KEA TECHNOLOGIES
9, rue d'Enghien
Paris ILE-DE-FRANCE
P: 33148240345.0
Employees: 56
Website: https://www.maunakeatech.com/
Find more stocks on Euronext Paris - Matif
Find more stocks on the EuroNext
Find more stocks on the European
Find competitors from the same sector on the EuroNext
Find competitors from the same industry on the EuroNext
Find stocks with similar TA and Setup ratings on the EuroNext
Find stocks with similar Fundamental rating on the EuroNext
Find the competitors with the best technical ratings on the EuroNext
Find the competitors with the best technical and setup ratings on the EuroNext
Find the competitors with the best fundamentals on the EuroNext
Find the competitors with the best valuation on the EuroNext
Find the competitors with the best dividend on the EuroNext
Find the competitors with the best analyst ratings on the EuroNext